在性结肠炎中使用螺旋藻的临床前临床和有限临床证据:系统性审查和元分析
Khadije Gorgi1, Zahra Ghanbarzadegan1, Amir Darkhosh1,2
1Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Advanced pharmaceutical bulletin
|March 16, 2026
概括
螺旋藻通过改进动物模型,对性结肠炎 (UC) 显示出有前途的前景.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 营养保健品 营养保健品
背景情况:
- 性结肠炎 (UC) 是一种慢性胃肠道炎症性疾病.
- 螺旋藻 (Arthrospira platensis) 是一种具有抗炎和抗氧化功能的天然剂.
研究的目的:
- 系统地审查关于螺旋藻对性结肠炎的影响的动物和临床研究.
- 评估螺旋藻作为UC治疗剂的潜力.
主要方法:
- 在PubMed,Scopus,Web of Science和Embase (1980年至2024年4月) 的系统文献搜索.
- 包括对哺乳动物模型或患有UC的患者的实验研究.
- 使用平均差异 (MD) 或标准化平均差异 (SMD) 与95%置信区间 (CI) 的聚合效应大小的元分析.
主要成果:
- 16项动物研究和3项随机对照试验 (RCT) 从1321份已识别的文件中被纳入.
- 螺旋藻在动物模型中表现出有益作用,包括改善体重,临床特征,结肠长度,氧化应激,炎症标志物和肠道微生物群.
- 在单一的RCT中,没有观察到对疾病活性的影响,但注意到生活质量,氧化应激,睡眠,压力和贫血的改善.
结论:
- 动物研究表明,螺旋藻对性结肠炎有积极影响.
- 数量有限的高质量的临床试验限制了关于螺旋藻在人类中的疗效的最终结论.
- 需要进一步严格的临床研究来证实螺旋藻在UC的治疗潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
594
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
594
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Inflammatory Bowel Disease IV: Pharmacological Management
899
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
899
Inflammatory Bowel Disease I: Ulcerative Colitis
1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
750
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
750
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K


